A Phase III Randomized Study of Cetuximab +/- Brivanib Alaninate (BMS-582664) in Patients With K-RAS Wild Type Tumors Previously Treated With Combination Chemotherapy for Metastatic Colorectal Carcinoma

Trial Profile

A Phase III Randomized Study of Cetuximab +/- Brivanib Alaninate (BMS-582664) in Patients With K-RAS Wild Type Tumors Previously Treated With Combination Chemotherapy for Metastatic Colorectal Carcinoma

Completed
Phase of Trial: Phase III

Latest Information Update: 06 Jun 2017

At a glance

  • Drugs Brivanib alaninate (Primary) ; Cetuximab
  • Indications Colorectal cancer
  • Focus Registrational; Therapeutic Use
  • Sponsors Bristol-Myers Squibb
  • Most Recent Events

    • 06 Jun 2017 Data from this trial was used to perform population pharmacokinetic (pop-pK) analysis of Cetuximab in patients with KRAS WT metastatic colorectal cancer , results (n=703) presented at the 53rd Annual Meeting of the American Society of Clinical Oncology
    • 11 Oct 2016 Results (n=570) analysing derived neutrophil to lymphocyte ratio (dNLR) as a prognostic biomarker for predicting efficacy in NCT00640471 and NCT00079066 studies presented at the 41st European Society for Medical Oncology Congress
    • 11 Oct 2013 Quality-of-life results published in Cancer.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top